EWTX — Edgewise Therapeutics, Inc. catalysts
Next verified catalyst
2027-01-01 — A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-01 (month) in 3mo
ESTIMATED |
READOUT
A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
Phase 2 · Duchenne Muscular Dystrophy |
EWTX Edgewise Therapeutics, Inc. | Sevasemten Dose 1, Sevasemten Dose 2, Se |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|